Nicotine Psychopharmacology

1. Front Matter

   Pages i-xiv

   PDF

2. Nicotine and Tobacco Consumption: Measurement and Trends

   1. Global Patterns of Nicotine and Tobacco Consumption

      • S. Katharine Hammond

      Pages 3-28

   2. Nicotine Chemistry, Metabolism, Kinetics and Biomarkers

      • Neal L. Benowitz, Janne Hukkanen, Peyton Jacob III

      Pages 29-60

   3. Nicotine Content and Delivery Across Tobacco Products

      • Mirjana V. Djordjevic, Kelly A. Doran

      Pages 61-82

3. Nicotine Pharmacology and Mechanisms of Action

   1. The Road to Discovery of Neuronal Nicotinic Cholinergic Receptor Subtypes

      • Allan C. Collins, Outi Salminen, Michael J. Marks, Paul Whiteaker, Sharon R. Grady

      Pages 85-112

   2. Magnetic Resonance Imaging Studies of Cigarette Smoking

      • Allen Azizian, John Monterosso, Joseph O'Neill, Edythe D. London

      Pages 113-143

   3. In vivo Brain Imaging of Human Exposure to Nicotine and Tobacco

      • Anil Sharma, Arthur L. Brody

      Pages 145-171

   4. Molecular and Cellular Mechanisms of Action of Nicotine in the CNS

      • Jacques Barik, Susan Wonnacott

      Pages 173-207

   5. The Neuronal Pathways Mediating the Behavioral and Addictive Properties of Nicotine

      • David J.K. Balfour

      Pages 209-233

   6. Molecular Genetics of Nicotine Metabolism

      • Jill C. Mwenifumbo, Rachel F. Tyndale

      Pages 235-259

   7. Sex Differences in Nicotine Action

      • Sakire Pogun, Gorkem Yararbas

      Pages 261-291

4. Nicotine Psychopharmacology

   1. Recognising Nicotine: The Neurobiological Basis of Nicotine Discrimination

      • Janice W. Smith, Ian P. Stolerman

      Pages 295-333

   2. Effects of Nicotine in Experimental Animals and Humans: An Update on Addictive Properties

      • Bernard Le Foll, Steven R. Goldberg

      Pages 335-367

   3. Discriminative Stimulus Effects of Nicotine in Humans

      • Kenneth A. Perkins

      Pages 369-400

   4. Rodent Models of Nicotine Withdrawal Syndrome

      • David H. Malin, Pilar Goyarzu

      Pages 401-434

5. Approaches, Challenges, and Experience in Assessing Free Nicotine

   1. Approaches, Challenges, and Experience in Assessing Free Nicotine

      • David L. Ashley, James F. Pankow, Ameer D. Tavakoli, Clifford H. Watson

      Pages 437-456

   2. Tobacco Industry Manipulation of Nicotine Dosing

      • Geoffrey Ferris Wayne, Carrie M. Carpenter

      Pages 457-485

   3. Pharmacotherapy for Tobacco Dependence

      • Reginald V. Fant, August R. Buchhalter, Albert C. Buchman, Jack E. Henningfield

      Pages 487-510

   4. Nicotine Psychopharmacology: Policy and Regulatory

      • Jack E. Henningfield, Mitch Zeller

      Pages 511-534

6. Back Matter

   Pages 535-544

   PDF

The fact that tobacco ingestion can affect how people feel and think has been known for millennia, placing the plant among those used spiritually, honori?cally, and habitually (Corti 1931; Wilbert 1987). However, the conclusion that nicotine - counted for many of these psychopharmacological effects did not emerge until the nineteenth century (Langley 1905). This was elegantly described by Lewin in 1931 as follows: “The decisive factor in the effects of tobacco, desired or undesired, is nicotine. . . ”(Lewin 1998). The use of nicotine as a pharmacological probe to und- stand physiological functioning at the dawn of the twentieth century was a landmark in the birth of modern neuropharmacology (Limbird 2004; Halliwell 2007), and led the pioneering researcher John Langley to conclude that there must exist some “- ceptive substance” to explain the diverse actions of various substances, including nicotine, when applied to muscle tissue (Langley 1905). Research on tobacco and nicotine progressed throughout the twentieth century, but much of this was from a general pharmacological and toxicological rather than a psychopharmacological perspective (Larson et al. 1961). There was some attention to the effects related to addiction, such as euphoria (Johnston 1941), tolerance (Lewin 1931), and withdrawal (Finnegan et al. 1945), but outside of research supported by the tobacco industry, addiction and psychopharmacology were not major foci for research (Slade et al. 1995; Hurt and Robertson 1998; Henning?eld et al. 2006; Henning?eld and Hartel 1999; Larson et al. 1961).

• Imaging
• Molecular
• Nicotine
• Psychopharmacology
• Receptor
• Syndrom
• genetics

• Pinney Associates, Bethesda, USA

  Jack E. Henningfield

• UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, USA

  Edythe D. London

• Center for Brain Research, Bornova, Ege University, Izmir, Turkey

  Sakire Pogun

Policies and ethics